Table 1 Patient phenotype based on self-reported penicillin history. *Patients presented with a combination of symptoms.+Patients include those with delayed OC and equivocal ST. aReactions already prior: no details documented by patients. bOther symptoms including: face swelling, teeth discoloration, cold sensation, blurred vision, subjective weakness, feet swelling, canker sore, throat discomfort, lost voice, headache, HSP. cOther treatments included: Epinephrine: 0, antihistamines: 22, salbutabmol: 0, IV fluids: 1, steroids: 2, other: 12 (given another steroid, topical steroids, calamine lotion, unclear)
Number of total patients (%) | Patient test negative (%) | Patient test positive+ (%) | |||
|---|---|---|---|---|---|
Total Number of patients | 181 | 176 | 5 | ||
Median age, median, (IQR) | 34.5 | 35 | 34 | ||
Referral source | General practitioner | 23 (12.7%) | 22 (12.5%) | 1 (20%) | |
OBGYN | 52 (28.7%) | 51 (30.0%) | 1 (20%) | ||
Registered midwife | 85 (47.0%) | 83 (47.1%) | 2 (40%) | ||
Other | 12 (6.6) | 11 (6.3%) | 1 (20%) | ||
Blank | 9 (5%) | 9 (5.1%) | 0 (0%) | ||
Type of penicillin used | Amoxicillin | 50 (27.6%) | 48 (27.3%) | 2 (40%) | |
Amoxicillin-Clavulanate | 2 (1.1%) | 1 (0.5%) | 1 (20%) | ||
Don’t know | 56 (30.3%) | 56 (31.8%) | 2 (40%) | ||
Other penicillin | 73 (40.3%) | 73 (41.5%) | 0 (0%) | ||
Time of reaction | > 10 years ago | 145 (80.1%) | 142 (80.1%) | 3 (60%) | |
> 5 years ago | 16 (8.8%) | 16 (9.1%) | 2 (40%) | ||
13mo to 5 years ag0 | 8 (4.4%) | 8 (4.5%) | 0 (0%) | ||
7 to 12 months ago | 1 (0.5%) | 1 (0.5%) | 0 (0%) | ||
3 to 6 months ago | 1 (0.5%) | 1 (0.5%) | 0 (0%) | ||
Don’t know | 10 (5.5%) | 10 (5.7%) | 0 (0%) | ||
Number of doses till reaction onset | > 7 days | 4 (2.2%) | 4 (2.3%) | 0 (0%) | |
4 to 7 days | 10 (5.5%) | 9 (5.1%) | 1 (20%) | ||
1 to 3 days | 29 (16.0%) | 29 (16.5%) | 0 (0%) | ||
1 dose | 23 (23%) | 22 (12.5%) | 1 (20%) | ||
Don’t know | 110 (60.8%) | 107 (60.8%) | 3 (60%) | ||
Reaction already present priora | 1 (0.5%) | 1 (0.5%) | 0 (0%) | ||
Blank (missing information) | 4 (2.2%) | 4 (2.3%) | 0 (0%) | ||
Time of symptom onset after most recent dose | < 1 h | 14 (7.7%) | 13 (7.4%) | 1 (20%) | |
1 to 2 h | 4 (2.2%) | 3 (1.7%) | 1 (20%) | ||
3 to 12 h | 12 (6.6%) | 12 (6.8%) | 0 (0%) | ||
13 to 24 h | 11 (6.1%) | 11 (6.3%) | 0 (0%) | ||
> 24 h | 1 (0.5%) | 1 (0.5%) | 0 (0%) | ||
Don’t know | 137 (75.7%) | 134 (77.8%) | 3 (60%) | ||
Symptom already present priora | 1 (0.5%) | 1 (0.5%) | 0 (0%) | ||
Blank (missing information) | 1 (0.5%) | 1 (0.5%) | 0 (0%) | ||
Patient reported reaction* | Skin | Macular/papular rash | 89 (49.2%) | 88 (50%) | 1 (20%) |
Urticaria | 59 (32.6%) | 56 (31.8%) | 3 (60%) | ||
Angioedema | 11 (6.1%) | 11 (6.3%) | 0 (0%) | ||
Blistering/peeling skin or mucous membrane | 1 (0.5%) | 1 (0.5%) | 0 (0%) | ||
Generalized pustulosis | 0 (0%) | 0 (0%) | 0 (0%) | ||
Erythema multiforme | 0 (0%) | 0 (0%) | 0 (0%) | ||
Respiratory | Cough | 0 (0%) | 0 (0%) | 0 (0%) | |
Wheeze | 3 (1.7%) | 3 (1.7%) | 0 (0%) | ||
Stridor | 0 (0%) | 0 (0%) | 0 (0%) | ||
Breathing difficulties | 6 (3.3%) | 6 (3.4%) | 1 (20%) | ||
Gastrointestinal | Nausea | 3 (1.7%) | 3 (1.7%) | 0 (0%) | |
Vomiting x1 | 8 (4.4%) | 8 (4.5%) | 0 (0%) | ||
Vomiting multiple times | 2 (1.1%) | 2 (1.1%) | 0 (0%) | ||
Abdominal discomfort | 0 (0%) | 0 (0%) | 0 (0%) | ||
Diarrhea | 1 (0.5%) | 1 (0.5%) | 0 (0%) | ||
Other | Palpitations | 0 (0%) | 0 (0%) | 0 (0%) | |
Decreased level of consciousness | 1 (0.5%) | 1 (0.5%) | 0 (0%) | ||
Arthritis/arthralgia | 2 (1.1%) | 2 (1.1%) | 0 (0%) | ||
Unexplained fever | 1 (0.5%) | 1 (0.5%) | 0 (0%) | ||
Liver or kidney involvement | 0 (0%) | 0 (0%) | 0 (0%) | ||
Otherb | 20 (11.0%) | 20 (11.4%) | 0 (0%) | ||
Treatment given | No | 65 (35.9%) | 64 (36.4%) | 1 (20%) | |
Yesc | 31 (17.1%) | 29 (16.5%) | 2 (40%) | ||
Don’t know | 83 (45.9%) | 81 (46.0%) | 2 (40%) | ||
Blank (missing information) | 2 (1.1%) | 2 (1.1%) | 0 (0%) | ||